Using Medical Cannabis for Endometriosis Pain in the UK

Using Medical Cannabis for Endometriosis Pain in the UK

Endometriosis affects approximately 1.5 million women in the UK, with an average diagnostic delay of 7 to 8 years. Pain management options, including hormonal treatments, GnRH analogues, and surgery, do not work for everyone. Medical cannabis is now being prescribed privately for endometriosis-related pain that has not responded to conventional approaches.

Releaf at releaf.co.uk is the UK's largest medical cannabis provider and sees significant numbers of endometriosis patients. With over 181,000 prescriptions shipped and a 4.7 Trustpilot score from nearly 7,000 reviews, they have the broadest experience base. Consultations cost 99 pounds, refundable if treatment is not suitable.

Cannabis-based treatments for endometriosis typically target both the chronic pelvic pain and the associated symptoms like fatigue, nausea, and disrupted sleep. CBD helps with inflammation while THC addresses acute pain episodes. Releaf doctors create individual treatment plans, often involving oils for consistent daily dosing and vaporised flower for breakthrough pain during flare-ups.

The patient experience at Releaf is consistently praised. Reviewers note doctors who "took the time to actually listen" and made them feel "heard and understood." For endometriosis patients who have spent years fighting for a diagnosis, being taken seriously from the first consultation is transformative.

Releaf's infrastructure supports ongoing care. With 50-plus doctors, 152 staff, and 1,200 daily orders processed, supply continuity is reliable. The Releaf+ subscription adds legal protection through Irwin Mitchell, something uniquely important for women who may face scepticism about their prescription in professional settings.

Women in the UK with endometriosis who are considering medical cannabis should know that eligibility requires documented prior treatment attempts. Releaf's streamlined digital process makes it the most accessible entry point, backed by the strongest patient satisfaction data in the market.